Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Observer-Blinded, Placebo-Controlled Phase I Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of One Dose Booster by A Lyophilized COVID-19 mRNA Vaccine in Adults Aged 18 to 60 Years

NCT05366296 is registered in ClinicalTrials.gov with Wuhan Recogen Biotechnology Co., Ltd. as lead sponsor.

NCT NCT05366296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05366296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Observer-Blinded, Placebo-Controlled Phase I Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of One Dose Booster by A Lyophilized COVID-19 mRNA Vaccine in Adults Aged 18 to 60 Years
Lead sponsor
Wuhan Recogen Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Withdrawn
Start date
July 31, 2022
Completion date
January 31, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pandemic